Pursuant to Regulations 30 and 33 of the SEBI LODR, 2015, Glenmark Pharmaceuticals has informed that Board has today at its meeting approved the Unaudited Financial Results for the First Quarter ended June 30, 2017.
The above information is a part of company’s filings submitted to BSE.